SYHA 1813
Alternative Names: SYHA-1813Latest Information Update: 28 Jul 2024
At a glance
- Originator Shanghai Institute of Materia Medica
- Developer Shanghai Runshi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Macrophage colony-stimulating factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Liquid)
- 11 Dec 2023 358320 CTP push: FET added, CTP linked (QC feedback incorporated)
- 06 Dec 2023 Shanghai Runshi Pharmaceutical plans a phase I pharmacokinetics and safety trial (In volunteers) in December 2023 (PO, Solution) (NCT06157918)